S&P 500   3,855.08 (+-0.01%)
DOW   30,971.60 (+0.04%)
QQQ   329.25 (+0.35%)
AAPL   142.73 (-0.13%)
MSFT   233.00 (+1.51%)
FB   284.38 (+2.29%)
GOOGL   1,902.72 (+0.45%)
AMZN   3,331.37 (+1.13%)
TSLA   883.02 (+0.25%)
NVDA   541.43 (-0.86%)
BABA   262.28 (+0.34%)
CGC   35.31 (+7.29%)
GE   11.56 (+5.19%)
MU   81.19 (-0.11%)
AMD   95.25 (+1.19%)
NIO   59.18 (-1.35%)
T   29.24 (+0.45%)
F   11.31 (+0.18%)
ACB   10.62 (+4.53%)
BA   202.97 (-0.19%)
DIS   169.76 (-1.24%)
NFLX   564.38 (+1.36%)
GILD   67.42 (-1.09%)
S&P 500   3,855.08 (+-0.01%)
DOW   30,971.60 (+0.04%)
QQQ   329.25 (+0.35%)
AAPL   142.73 (-0.13%)
MSFT   233.00 (+1.51%)
FB   284.38 (+2.29%)
GOOGL   1,902.72 (+0.45%)
AMZN   3,331.37 (+1.13%)
TSLA   883.02 (+0.25%)
NVDA   541.43 (-0.86%)
BABA   262.28 (+0.34%)
CGC   35.31 (+7.29%)
GE   11.56 (+5.19%)
MU   81.19 (-0.11%)
AMD   95.25 (+1.19%)
NIO   59.18 (-1.35%)
T   29.24 (+0.45%)
F   11.31 (+0.18%)
ACB   10.62 (+4.53%)
BA   202.97 (-0.19%)
DIS   169.76 (-1.24%)
NFLX   564.38 (+1.36%)
GILD   67.42 (-1.09%)
S&P 500   3,855.08 (+-0.01%)
DOW   30,971.60 (+0.04%)
QQQ   329.25 (+0.35%)
AAPL   142.73 (-0.13%)
MSFT   233.00 (+1.51%)
FB   284.38 (+2.29%)
GOOGL   1,902.72 (+0.45%)
AMZN   3,331.37 (+1.13%)
TSLA   883.02 (+0.25%)
NVDA   541.43 (-0.86%)
BABA   262.28 (+0.34%)
CGC   35.31 (+7.29%)
GE   11.56 (+5.19%)
MU   81.19 (-0.11%)
AMD   95.25 (+1.19%)
NIO   59.18 (-1.35%)
T   29.24 (+0.45%)
F   11.31 (+0.18%)
ACB   10.62 (+4.53%)
BA   202.97 (-0.19%)
DIS   169.76 (-1.24%)
NFLX   564.38 (+1.36%)
GILD   67.42 (-1.09%)
S&P 500   3,855.08 (+-0.01%)
DOW   30,971.60 (+0.04%)
QQQ   329.25 (+0.35%)
AAPL   142.73 (-0.13%)
MSFT   233.00 (+1.51%)
FB   284.38 (+2.29%)
GOOGL   1,902.72 (+0.45%)
AMZN   3,331.37 (+1.13%)
TSLA   883.02 (+0.25%)
NVDA   541.43 (-0.86%)
BABA   262.28 (+0.34%)
CGC   35.31 (+7.29%)
GE   11.56 (+5.19%)
MU   81.19 (-0.11%)
AMD   95.25 (+1.19%)
NIO   59.18 (-1.35%)
T   29.24 (+0.45%)
F   11.31 (+0.18%)
ACB   10.62 (+4.53%)
BA   202.97 (-0.19%)
DIS   169.76 (-1.24%)
NFLX   564.38 (+1.36%)
GILD   67.42 (-1.09%)
Log in
NASDAQ:VYGR

Voyager Therapeutics Stock Forecast, Price & News

$8.74
+0.05 (+0.58 %)
(As of 01/26/2021 11:03 AM ET)
Add
Compare
Today's Range
$8.67
Now: $8.74
$8.94
50-Day Range
$7.15
MA: $8.22
$9.28
52-Week Range
$6.26
Now: $8.74
$14.62
Volume2,725 shs
Average Volume411,554 shs
Market Capitalization$327.45 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and alpha-synuclein program for synucleinopathies, Parkinson's disease, Lewy Body Dementia, and multiple system atrophy. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Voyager Therapeutics logo

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

196th out of 1,922 stocks

Biological Products, Except Diagnostic Industry

25th out of 177 stocks

Analyst Opinion: 4.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VYGR
CUSIPN/A
Phone857-259-5340
Employees185
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$104.39 million
Book Value$2.68 per share

Profitability

Net Income$-43,600,000.00

Miscellaneous

Market Cap$327.45 million
Next Earnings Date3/2/2021 (Estimated)
OptionableOptionable
$8.74
+0.05 (+0.58 %)
(As of 01/26/2021 11:03 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VYGR News and Ratings via Email

Sign-up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions

How has Voyager Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Voyager Therapeutics' stock was trading at $9.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VYGR stock has decreased by 6.3% and is now trading at $8.84.
View which stocks have been most impacted by COVID-19
.

Is Voyager Therapeutics a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last twelve months. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Voyager Therapeutics stock.
View analyst ratings for Voyager Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Voyager Therapeutics?

Wall Street analysts have given Voyager Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Voyager Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Voyager Therapeutics' next earnings date?

Voyager Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for Voyager Therapeutics
.

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) issued its earnings results on Monday, November, 9th. The company reported $2.27 earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $2.46. The company had revenue of $117.84 million for the quarter, compared to analyst estimates of $43.34 million. Voyager Therapeutics had a negative net margin of 60.61% and a negative trailing twelve-month return on equity of 66.46%.
View Voyager Therapeutics' earnings history
.

What price target have analysts set for VYGR?

12 brokerages have issued 1-year price targets for Voyager Therapeutics' shares. Their forecasts range from $10.00 to $26.00. On average, they expect Voyager Therapeutics' stock price to reach $15.23 in the next year. This suggests a possible upside of 72.3% from the stock's current price.
View analysts' price targets for Voyager Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Voyager Therapeutics' key competitors?

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the following people:
  • Mr. G. Andre Turenne, CEO, Pres & Director (Age 47, Pay $797.68k)
  • Mr. Robert W. Hesslein, Sr. VP & Gen. Counsel (Age 68, Pay $544.4k)
  • Dr. Omar Khwaja M.D., Ph.D., Chief Medical Officer and Head of R&D (Age 51, Pay $698.59k)
  • Dr. Steven M. Paul M.D., Exec. Science Advisor & Director (Age 70, Pay $333.09k)
  • Dr. Krystof Bankiewicz M.D., Ph.D., Founder
  • Dr. Guangping Gao, Founder
  • Dr. Mark A. Kay, Founder (Age 63)
  • Dr. Phillip D. Zamore, Founder
  • Ms. Allison Dorval, CFO & Principal Accounting Officer (Age 45)
  • Mr. Paul Cox, VP of Investor Relations

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Strs Ohio (0.21%) and XTX Markets LLC (0.03%). Company insiders that own Voyager Therapeutics stock include Allison Dorval, Andre Turenne, Matthew P Ottmer, Neurocrine Biosciences Inc, Omar Khwaja and Robert W Hesslein.
View institutional ownership trends for Voyager Therapeutics
.

Which institutional investors are buying Voyager Therapeutics stock?

VYGR stock was purchased by a variety of institutional investors in the last quarter, including Strs Ohio, and XTX Markets LLC.
View insider buying and selling activity for Voyager Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $8.84.

How big of a company is Voyager Therapeutics?

Voyager Therapeutics has a market capitalization of $331.20 million and generates $104.39 million in revenue each year. The company earns $-43,600,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. Voyager Therapeutics employs 185 workers across the globe.

What is Voyager Therapeutics' official website?

The official website for Voyager Therapeutics is www.voyagertherapeutics.com.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-5340 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.